title: [Not Available].
abstract: Levetiracetam is an anticonvulsant drug used to treat partial seizures, myoclonic seizures of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. A review of the literature with an evidence-based medicine method highlighted parameters (age, renal failure, pregnancy, combination with other anticonvulsant drugs) which affect levetiracetam pharmacokinetics but no significant relationship between plasma concentration of levetiracetam and efficacy or toxicity. Concentrations usually observed in therapeutics is from 6 to 18 mg/L. However, the determination of an individual therapeutic concentration, associated with an effective and well tolerated therapy, could be recommended particularly before pregnancy. Consequently, therapeutic drug monitoring of leve-tiracetam which is not currently recommended could be possibly useful in specific clinical situations.
authors.affiliation: Service de Pharmacologie Clinique, CHU de Nantes, Nantes, France; EA 4275 Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Faculté de Médecine - Pharmacie, Université de Nantes, France. Electronic address: eric.dailly@chu-nantes.fr.
authors.forename: Eric
authors.initials: E
authors.lastname: Dailly
authors.affiliation: Service de Pharmacologie Clinique, CHU de Nantes, Nantes, France; EA 4275 Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Faculté de Médecine - Pharmacie, Université de Nantes, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Bouquié
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
keywords: levetiracetam; lévétiracétam; suivi thérapeutique pharmacologique; therapeutic drug monitoring